+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07579195

Study of Radiation Therapy or Bladder Removal After Initial Response to Enfortumab Vedotin and Pembrolizumab in Advanced Muscle Invasive Bladder Cancer

Led by University of Washington · Updated on 2026-08-25

12

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new treatment approach for patients with advanced bladder cancer that cannot be surgically removed, has spread to nearby lymph nodes or a limited number of distant sites, and who have responded to initial treatment with enfortumab vedotin and pembrolizumab. This trial aims to assess whether adding local consolidative treatments like radiation therapy or bladder removal surgery can safely eliminate remaining cancer and delay progression while reducing long-term side effects from ongoing systemic therapy. The study also includes biomarker testing using circulating tumor DNA to personalize treatment decisions. Participants receive consolidative therapy based on their response to initial treatment. Those with residual tumor in the bladder may undergo radiation therapy daily for 4 weeks combined with chemotherapy or have radical cystectomy surgery. Metastatic sites outside the bladder may be treated with targeted stereotactic body radiation therapy. After these treatments, participants may continue observation or maintenance pembrolizumab until disease progression or other criteria are met. Throughout the study, participants undergo imaging scans such as CT, MRI, and PETCT, along with cystoscopy and repeat bladder tumor resection as needed. Blood and urine samples are collected for biomarker analysis. Follow-up visits occur every 3 months for up to one year to monitor cancer progression, side effects, quality of life, and overall survival. The main outcome is the completion rate of the treatment protocol within 12 months.

CONDITIONS

Brief Title

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

Research Team

T

T. Martin Ma, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here